CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Income Statement [Abstract]
Net revenues	$ 138,503	$ 122,182	$ 509,338
Cost of revenues	33,689	29,614	128,280
Gross profit	104,814	92,568	381,058
Operating costs and expenses:
Research, development and clinical studies	51,598	59,704	223,062
Sales and marketing	55,206	51,169	226,809
General and administrative	39,530	41,944	164,057
Total operating costs and expenses	146,334	152,817	613,928
Operating income (loss)	(41,520)	(60,249)	(232,870)
Financial income (expenses), net	9,878	9,169	41,130
Income (loss) before income tax	(31,642)	(51,080)	(191,740)
Income tax	7,118	1,981	15,303
Net income (loss)	$ (38,760)	$ (53,061)	$ (207,043)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.36)	$ (0.50)	$ (1.95)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.36)	$ (0.50)	$ (1.95)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	107,266,198	105,667,072	106,391,178
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	107,266,198	105,667,072	106,391,178